The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...

The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.

One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the weight loss drug Wegovy) were about 40 to 70 percent less likely to be ...

People who exercise throughout their lives have a better chance of avoiding dementia - even if they show signs of diseases like Alzheimer's, finds a new study led by UCL researchers.

Funded by a $3 million National Institutes of Health grant, the two universities plan to study the relationship between two ...

The Alzheimer's Association Illinois Chapter Junior Board's signature fundraising event Paint The Night Purple is coming up soon. It's an important event to help raise awareness for Alzheimer's ...

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and (Nasdaq: BIIB, Corporate headquarters: Cambridge, ...

According to recent research published in ‘Alzheimer's & Dementia’, delays in entering the rapid eye movement (REM) sleep phase may signal early signs of Alzheimer's disease. The study found that ...

Taking longer to drift into the dreaming phase – known as rapid eye movement (REM) sleep – could be an early sign of ...

Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.

Scientists have used advanced X-ray phase-contrast tomography (XPCT) to uncover how gut health may influence Alzheimer’s disease.